2IVB.F - Indivior PLC
| Previous close | 17.50 |
| Open | 17.18 |
| Bid | 18.32 x N/A |
| Ask | 18.62 x N/A |
| Day's range | 17.18 - 18.54 |
| 52-week range | 15.07 - 22.81 |
| Volume | |
| Avg. volume | 30 |
| Market cap | 2.556B |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 June 2016 |
| 1y target est | N/A |
PR NewswireIndivior To Participate In Upcoming Investor Conferences
Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events:
- PR Newswire
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
Indivior PLC (LSE: INDV) today announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares is now available at www.sec.gov and under the "Investors" section of the Company's website (www.indivior.com). Trading in Indivior's ordinary shares on the NASDAQ Global Select Market is expected to commence at the open on June 12, 2023, subject to approval by the U.S. Securities & Exchange Commission (SEC) and NASDAQ. Indivior will retain its prem
- PR Newswire
Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.2 OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respirat
- PR Newswire
Indivior Announces Q1 2023 Financial Results
Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.
- PR Newswire
Indivior To Participate In Bank of America Global Healthcare Conference 2023
Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event:
- PR Newswire
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc. ("Opiant"). The transaction strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl.
- PR Newswire
FY 2022 Financial Results Announced
Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at www.indivior.com.
GlobeNewswireOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign In
GlobeNewswireOpiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute th
Simply Wall St.Investing in Indivior (LON:INDV) three years ago would have delivered you a 861% gain
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. But when you hold the...
- Simply Wall St.
Should You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- PR Newswire
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
GlobeNewswireIndivior PLC to Acquire Opiant Pharmaceuticals
Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant’s closing share price of November 11, 2022, and 99% premium to Opiant’s 30-day volume-weighted average share price; total consideration, inclusive of p
- PR Newswire
Indivior To Acquire Opiant Pharmaceuticals
Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) ("Opiant") today announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up to $8.00 per share in contingent value rights ("CVRs") that may become payable in the event that certain net revenue milestones are achieved during the relevant
- Simply Wall St.
Indivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)
Indivior ( LON:INDV ) Third Quarter 2022 Results Key Financial Results Revenue: US$232.0m (up 24% from 3Q 2021). Net...
- PR Newswire
Indivior Announces Q3 2022 Financial Results
Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com.